Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
  • The following terms were not found in PubMed: review literature[mh], consumerj[sb].
  • See the search details.

Results: 1 to 20 of 230

1.

Meige syndrome: what's in a name?

LeDoux MS.

Parkinsonism Relat Disord. 2009 Aug;15(7):483-9. Epub 2009 May 19. Review.PMID: 19457699 [PubMed - indexed for MEDLINE]Related articles

2.

FL-41 tint improves blink frequency, light sensitivity, and functional limitations in patients with benign essential blepharospasm.

Blackburn MK, Lamb RD, Digre KB, Smith AG, Warner JE, McClane RW, Nandedkar SD, Langeberg WJ, Holubkov R, Katz BJ.

Ophthalmology. 2009 May;116(5):997-1001.PMID: 19410958 [PubMed - indexed for MEDLINE]Related articles

3.

High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference?

Boyle MH, McGwin G Jr, Flanagan CE, Vicinanzo MG, Long JA.

Ophthal Plast Reconstr Surg. 2009 Mar-Apr;25(2):81-4.PMID: 19300145 [PubMed - indexed for MEDLINE]Related articles

4.

Relationship between various clinical outcome assessments in patients with blepharospasm.

Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G.

Mov Disord. 2009 Feb 15;24(3):407-13.PMID: 19053054 [PubMed - indexed for MEDLINE]Related articles

5.

Update on blepharospasm: report from the BEBRF International Workshop.

Hallett M, Evinger C, Jankovic J, Stacy M; BEBRF International Workshop.

Neurology. 2008 Oct 14;71(16):1275-82. Review.PMID: 18852443 [PubMed - indexed for MEDLINE]Related articlesFree article

6.

Videonystagmography as a tool to assess blepharospasm before and after botulinum toxin injection.

Casse G, Adenis JP, Sauvage JP, Robert PY.

Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1307-14. Epub 2008 Jun 26.PMID: 18581129 [PubMed - indexed for MEDLINE]Related articles

7.

Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology. 2008 May 6;70(19):1699-706.PMID: 18458230 [PubMed - indexed for MEDLINE]Related articles

8.

The use of botulinum toxin in head and face medicine: an interdisciplinary field.

Laskawi R.

Head Face Med. 2008 Mar 10;4:5. Review.PMID: 18331633 [PubMed - indexed for MEDLINE]Related articlesFree article

9.

Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.

Truong D, Comella C, Fernandez HH, Ondo WG; Dysport Benign Essential Blepharospasm Study Group.

Parkinsonism Relat Disord. 2008;14(5):407-14. Epub 2008 Mar 5.PMID: 18325821 [PubMed - indexed for MEDLINE]Related articles

10.

Drug-induced ocular disorders.

Li J, Tripathi RC, Tripathi BJ.

Drug Saf. 2008;31(2):127-41. Review.PMID: 18217789 [PubMed - indexed for MEDLINE]Related articles

11.

What is new in the era of focal dystonia treatment? Botulinum injections and more.

Cetinkaya A, Brannan PA.

Curr Opin Ophthalmol. 2007 Sep;18(5):424-9. Review.PMID: 17700237 [PubMed - indexed for MEDLINE]Related articles

12.

Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.

Sheffield JK, Jankovic J.

Expert Rev Neurother. 2007 Jun;7(6):637-47. Review.PMID: 17563247 [PubMed - indexed for MEDLINE]Related articles

13.

Botulinum toxin in the treatment of blepharospasm and hemifacial spasm.

Kenney C, Jankovic J.

J Neural Transm. 2008;115(4):585-91. Epub 2007 Jun 11. Review.PMID: 17558461 [PubMed - indexed for MEDLINE]Related articles

14.

Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm.

Ochudlo S, Bryniarski P, Opala G.

Parkinsonism Relat Disord. 2007 Dec;13(8):505-8. Epub 2007 May 31.PMID: 17543569 [PubMed - indexed for MEDLINE]Related articles

15.

Botulinum toxin in movement disorders.

Papapetropoulos S, Singer C.

Semin Neurol. 2007 Apr;27(2):183-94. Review.PMID: 17390263 [PubMed - indexed for MEDLINE]Related articles

16.

Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

Jost WH, Blümel J, Grafe S.

Drugs. 2007;67(5):669-83. Review.PMID: 17385940 [PubMed - indexed for MEDLINE]Related articles

17.

Complications of botulinum toxin type A.

Carruthers J, Carruthers A.

Facial Plast Surg Clin North Am. 2007 Feb;15(1):51-4, vi. Review.PMID: 17317555 [PubMed - indexed for MEDLINE]Related articles

18.

The eyelid and its contribution to eye movements.

Helmchen C, Rambold H.

Dev Ophthalmol. 2007;40:110-31. Review.PMID: 17314482 [PubMed - indexed for MEDLINE]Related articles

19.

A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm.

Rieder CR, Schestatsky P, Socal MP, Monte TL, Fricke D, Costa J, Picon PD.

Clin Neuropharmacol. 2007 Jan-Feb;30(1):39-42.PMID: 17272968 [PubMed - indexed for MEDLINE]Related articles

20.

Are nongenetic triggers for dystonia type-specific? A study exploring scoliosis in blepharospasm.

Martino D, Defazio G, Abbruzzese G, Marchese R, Fabbrini G, Decembrino V, Berardelli A.

Mov Disord. 2007 Mar 15;22(4):576-8.PMID: 17260341 [PubMed - indexed for MEDLINE]Related articles

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Find related data

Search details

» See more...